The POET II trial supports stopping antibiotics once patients with infective endocarditis are clinically stable, potentially shortening treatment durations. The trial suggested relapse rates rise in general, but outcomes depended on patient selection and careful stability criteria. This matters for hospital antimicrobial policies because endocarditis regimens drive long inpatient stays and broad-spectrum exposure. Shorter courses can reduce toxicity and resource use, but the safety trade-off requires tighter operational thresholds. Clinicians and antimicrobial stewardship teams are likely to focus on defining stability endpoints and ensuring relapse monitoring protocols before adopting shorter regimens at scale.